Ami Organics IPO (Initial Public Offering) will open for subscription on September 1, 2021 and will remain available for bid until September 3, 2021. ₹569.64 crore public issue includes new issues totaling up to ₹200 crore and Offer for Sale (OFS) with a grand total of up to ₹369.64 million euros. Although two more trading sessions remain until the opening of this public offering, the gray market has started to give signals for the upcoming IPO. According to market observers, Ami Organics is IPO GMP today ₹68 compared to its issue price range of ₹603 tons ₹610 per share.
Ami Organics share price in the gray market
According to market observers, Ami Organics shares are trading at a premium of. acted ₹68 on the gray market. They said that Ami Organics shares in the gray market on Thursday at a premium of. were offered for sale ₹58 per equity share. On Friday it nudged ₹2 and hit ₹60. Observers said the continued rise in Ami Organics’ IPO GMP reflects the positive sentiment for the public issue in the gray market.
What this GMP means
Market observers said that the gray market premium represents the expected stock market growth in relation to the respective public issue. How Ami Organics IPO GMP is today ₹68, it simply means that the gray market expects Ami Organics to go public at around ₹678 ( ₹610 + ₹68) – means that the gray market is expecting a double-digit premium from the public offering while two more trading sessions remain before the IPO is available for subscription.
Talking About The Basics of Supporting Ami Organics’ IPO; Arijit Malakar, Head of Research at Ashika Stock Broking, said, “Ami Organics is a research and development driven manufacturer of pharmaceutical intermediates and specialty chemicals, with pharmaceutical intermediates accounting for nearly 88 percent of sales while specialty chemicals accounting for 5 percent. The company has more than 400 products in its portfolio in 17 major therapeutic areas. It has a diversified portfolio and is not dependent on individual products or individual customers. His customers include both domestic and international companies with export shares of more than 50 percent of sales. With a sales base of ₹300 crore it is small compared to other large publicly traded pharma API players. Additionally, the company is valued at a P / E ratio of 41x post-issue versus the industry average of 45x, which is fair valued. This leaves little room for a significant upward trend in the IPO price. However, the pharma API sector has a good pull and you can look at this company with a better entry point after listing. “
Subscribe to something Mint newsletter
* Please enter a valid email
* Thank you for subscribing to our newsletter.
Never miss a story again! Stay connected and informed with Mint. Download our app now !!